Literature DB >> 3101065

Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies.

Y Sultan, F Rossi, M D Kazatchkine.   

Abstract

Plasma samples obtained from a patient 6 wk, 6 months, and 4 yr after recovery from anti-VIII:C (anti-hemophilic factor, where VIII:C = factor VIII procoagulant activity) autoimmune disease were found to contain antibodies that inhibited anti-VIII:C activity in the patient's prerecovery plasma and in the plasma of two other patients with anti-VIII:C autoantibodies. F(ab')2 fragments from postrecovery IgG suppressed anti-VIII:C activity in F(ab')2 fragments from prerecovery IgG within a narrow range of molar ratios. Anti-VIII:C activity in F(ab')2 autoantibodies was also inhibited by F(ab')2 fragments from polyspecific therapeutic immunoglobulins prepared from a large pool of normal donors (IVIg). IgG from prerecovery plasma bound to F(ab')2 from postrecovery IgG and to F(ab')2 from IVIg, as assessed by ELISA. Affinity chromatography experiments demonstrated that F(ab')2 from postrecovery IgG preferentially bound anti-VIII:C antibodies among F(ab')2 fragments from prerecovery plasma containing anti-VIII:C autoantibodies. F(ab')2 from prerecovery plasma bound in higher amounts to postrecovery F(ab')2 than to IVIg. Insolubilized F(ab')2 fragments from postrecovery plasma also bound F(ab')2 fragments prepared from the plasma of another patient with anti-VIII:C autoimmune disease, although in lesser amounts than the patient's own prerecovery anti-VIII:C F(ab')2 antibodies. These observations suggest that human anti-VIII:C autoantibodies share idiotypic determinants and that spontaneous recovery from anti-VIII:C autoimmune disease occurs through idiotypic suppression of autoantibodies. In patients who recover from autoimmune disease and in patients in whom autoantibodies have been suppressed by infusions of IVIg, antiidiotypic antibodies, possibly by providing internal images of the antigen, may have shifted the immune system toward the steady-state equilibrium that prevents autoimmunity in normal individuals.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3101065      PMCID: PMC304309          DOI: 10.1073/pnas.84.3.828

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  9 in total

1.  Letter: A more uniform measurement of factor VIII inhibitors.

Authors: 
Journal:  Thromb Diath Haemorrh       Date:  1975-12-15

2.  The mode of action of antibodies which destroy factor VIII. II. Antibodies which give complex concentration graphs.

Authors:  R Biggs; D E Austen; K W Denson; R Borrett; C R Rizza
Journal:  Br J Haematol       Date:  1972-08       Impact factor: 6.998

3.  The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs.

Authors:  R Biggs; D E Austen; K W Denson; C R Rizza; R Borrett
Journal:  Br J Haematol       Date:  1972-08       Impact factor: 6.998

4.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

5.  Evidence of unique idiotypic determinants and similar idiotypic determinants on human antithyroglobulin antibodies.

Authors:  T Matsuyama; J Fukumori; H Tanaka
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

Review 6.  Idiotypic networks and other preconceived ideas.

Authors:  N K Jerne
Journal:  Immunol Rev       Date:  1984-06       Impact factor: 12.988

Review 7.  Genetics, expression, and function of idiotypes.

Authors:  K Rajewsky; T Takemori
Journal:  Annu Rev Immunol       Date:  1983       Impact factor: 28.527

8.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

9.  A survey of 215 non-hemophilic patients with inhibitors to Factor VIII.

Authors:  D Green; K Lechner
Journal:  Thromb Haemost       Date:  1981-06-30       Impact factor: 5.249

  9 in total
  24 in total

1.  Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro.

Authors:  I N van Schaik; I Lundkvist; M Vermeulen; A Brand
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

2.  The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids.

Authors:  W M Vuist; I N Van Schaik; M Van Lint; A Brand
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

3.  Natural recovery from antiglomerular basement membrane glomerulonephritis is associated with glomeruli-infiltrating CD8α+CD11c+MHC class II+ cells.

Authors:  Cindy Zhou; Julie Robertson; Jean Wu; Todd Bartkowiak; Kiana Parker; John McMahon; Ya-Huan Lou
Journal:  Am J Nephrol       Date:  2011-11-07       Impact factor: 3.754

4.  Specificity and cross-reactive idiotypes of anti-gp330 autoantibodies in active Heymann nephritis.

Authors:  R J Specht Grijp-Glandorf; E De Heer; C C Dekker-Nooren; M R Daha; L A Van Es
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

Review 5.  Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.

Authors:  S V Kaveri; G Dietrich; V Hurez; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

6.  Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.

Authors:  M Algiman; G Dietrich; U E Nydegger; D Boieldieu; Y Sultan; M D Kazatchkine
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

7.  Intravenous immunoglobulins. Current understanding and future directions.

Authors:  S Jolles; S V Kaveri; J Orange
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

Review 8.  Intravenous immunoglobulins--understanding properties and mechanisms.

Authors:  A Durandy; S V Kaveri; T W Kuijpers; M Basta; S Miescher; J V Ravetch; R Rieben
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

9.  Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies.

Authors:  G Dietrich; M D Kazatchkine
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

10.  Detection and purification of antiidiotypic antibody against anti-DNA in intravenous immune globulin.

Authors:  M J Evans; R Suenaga; N I Abdou
Journal:  J Clin Immunol       Date:  1991-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.